Targeting	0	9	O
angiogenesis	10	22	O
:	22	23	O
progress	24	32	O
with	33	37	O
anti	38	42	O
-	42	43	O
VEGF	43	47	B-Gene_or_gene_product
treatment	48	57	O
with	58	62	O
large	63	68	O
molecules	69	78	O
.	78	79	O

Angiogenesis	81	93	O
-	93	94	O
-	94	95	O
one	95	98	O
of	99	101	O
the	102	105	O
hallmarks	106	115	O
of	116	118	O
cancer	119	125	O
-	125	126	O
-	126	127	O
has	127	130	O
emerged	131	138	O
as	139	141	O
a	142	143	O
valid	144	149	O
therapeutic	150	161	O
target	162	168	O
in	169	171	O
oncology	172	180	O
.	180	181	O

The	182	185	O
VEGF	186	190	B-Gene_or_gene_product
system	191	197	O
represents	198	208	O
a	209	210	O
key	211	214	O
mediator	215	223	O
of	224	226	O
tumor	227	232	B-Pathological_formation
-	232	233	O
initiated	233	242	O
angiogenesis	243	255	O
and	256	259	O
the	260	263	O
first	264	269	O
target	270	276	O
of	277	279	O
antiangiogenesis	280	296	O
agents	297	303	O
introduced	304	314	O
in	315	317	O
clinical	318	326	O
practice	327	335	O
.	335	336	O

Although	337	345	O
anti	346	350	O
-	350	351	O
VEGF	351	355	B-Gene_or_gene_product
therapies	356	365	O
have	366	370	O
clearly	371	378	O
demonstrated	379	391	O
antitumor	392	401	B-Pathological_formation
efficacy	402	410	O
in	411	413	O
various	414	421	O
malignancies	422	434	O
,	434	435	O
especially	436	446	O
when	447	451	O
combined	452	460	O
with	461	465	O
conventional	466	478	O
cytotoxic	479	488	O
chemotherapy	489	501	O
,	501	502	O
their	503	508	O
mechanism	509	518	O
of	519	521	O
action	522	528	O
is	529	531	O
not	532	535	O
fully	536	541	O
understood	542	552	O
.	552	553	O

This	554	558	O
Review	559	565	O
will	566	570	O
discuss	571	578	O
the	579	582	O
rationale	583	592	O
for	593	596	O
using	597	602	O
antiangiogenic	603	617	O
compounds	618	627	O
and	628	631	O
will	632	636	O
focus	637	642	O
on	643	645	O
large	646	651	O
molecules	652	661	O
,	661	662	O
such	663	667	O
as	668	670	O
antibodies	671	681	O
,	681	682	O
that	683	687	O
target	688	694	O
the	695	698	O
VEGF	699	703	B-Gene_or_gene_product
system	704	710	O
.	710	711	O

Clinical	712	720	O
data	721	725	O
on	726	728	O
bevacizumab	729	740	B-Drug_or_compound
is	741	743	O
discussed	744	753	O
in	754	756	O
detail	757	763	O
.	763	764	O

Predictive	765	775	O
markers	776	783	O
for	784	787	O
anti	788	792	O
-	792	793	O
VEGF	793	797	B-Gene_or_gene_product
agents	798	804	O
have	805	809	O
not	810	813	O
yet	814	817	O
been	818	822	O
identified	823	833	O
and	834	837	O
questions	838	847	O
regarding	848	857	O
the	858	861	O
usefulness	862	872	O
of	873	875	O
bevacizumab	876	887	B-Drug_or_compound
in	888	890	O
the	891	894	O
adjuvant	895	903	O
setting	904	911	O
as	912	914	O
well	915	919	O
as	920	922	O
its	923	926	O
continued	927	936	O
use	937	940	O
beyond	941	947	O
progression	948	959	O
remain	960	966	O
unanswered	967	977	O
,	977	978	O
in	979	981	O
spite	982	987	O
of	988	990	O
negative	991	999	O
data	1000	1004	O
on	1005	1007	O
bevacizumab	1008	1019	B-Drug_or_compound
in	1020	1022	O
treating	1023	1031	O
patients	1032	1040	B-Organism
with	1041	1045	O
adjuvant	1046	1054	O
colon	1055	1060	B-Pathological_formation
cancer	1061	1067	I-Pathological_formation
.	1067	1068	O

Nonetheless	1069	1080	O
,	1080	1081	O
anti	1082	1086	O
-	1086	1087	O
VEGF	1087	1091	B-Gene_or_gene_product
therapy	1092	1099	O
has	1100	1103	O
enhanced	1104	1112	O
the	1113	1116	O
arsenal	1117	1124	O
of	1125	1127	O
anticancer	1128	1138	O
therapies	1139	1148	O
and	1149	1152	O
has	1153	1156	O
provided	1157	1165	O
new	1166	1169	O
insights	1170	1178	O
into	1179	1183	O
the	1184	1187	O
biology	1188	1195	O
of	1196	1198	O
malignancy	1199	1209	O
.	1209	1210	O

